Randomized Phase II Study of Multipeptide Vaccination With or Without Regulatory T Cell Depletion Using Ontak in Patients With Metastatic Melanoma

Trial Profile

Randomized Phase II Study of Multipeptide Vaccination With or Without Regulatory T Cell Depletion Using Ontak in Patients With Metastatic Melanoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Denileukin diftitox (Primary) ; Adjuvants; Adjuvants; Granulocyte-macrophage colony-stimulating factors; Granulocyte-macrophage colony-stimulating factors; MelanA gp100 MAGE3 NA174 peptide vaccine; MelanA gp100 MAGE3 NA174 peptide vaccine
  • Indications Malignant melanoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 25 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 25 Aug 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 14 Aug 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top